Article ; Online: Exploiting the therapeutic implications of KRAS inhibition on tumor immunity.
2024 Volume 42, Issue 3, Page(s) 338–357
Abstract: Over the past decade, RAS oncogenic proteins have transitioned from being deemed undruggable to having two clinically approved drugs, with several more in advanced stages of development. Despite the initial benefit of KRAS-G12C inhibitors for patients ... ...
Abstract | Over the past decade, RAS oncogenic proteins have transitioned from being deemed undruggable to having two clinically approved drugs, with several more in advanced stages of development. Despite the initial benefit of KRAS-G12C inhibitors for patients with tumors harboring this mutation, the rapid emergence of drug resistance underscores the urgent need to synergize these inhibitors with other therapeutic approaches to improve outcomes. RAS mutant tumor cells can create an immunosuppressive tumor microenvironment (TME), suggesting an increased susceptibility to immunotherapies following RAS inhibition. This provides a rationale for combining RAS inhibitory drugs with immune checkpoint blockade (ICB). However, achieving this synergy in the clinical setting has proven challenging. Here, we explore how understanding the impact of RAS mutant tumor cells on the TME can guide innovative approaches to combining RAS inhibition with immunotherapies, review progress in both pre-clinical and clinical stages, and discuss challenges and future directions. |
---|---|
MeSH term(s) | Humans ; Proto-Oncogene Proteins p21(ras) ; Neoplasms ; Mutation ; Immunotherapy ; Tumor Microenvironment |
Chemical Substances | Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2) ; KRAS protein, human |
Language | English |
Publishing date | 2024-03-12 |
Publishing country | United States |
Document type | Journal Article ; Review |
ZDB-ID | 2078448-X |
ISSN | 1878-3686 ; 1535-6108 |
ISSN (online) | 1878-3686 |
ISSN | 1535-6108 |
DOI | 10.1016/j.ccell.2024.02.012 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 5650: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MG 104: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.